You are here

Amgen Terminates Study of Ganitumab in Metastatic Pancreatic Cancer

Drug was unlikely to improve overall survival when combined with gemcitabine

Based on the review of a preplanned interim analysis, the DMC concluded that the addition of ganitumab (AMG 479) to gemcitabine was unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared with gemcitabine alone.

The GAMMA study was conducted to determine whether ganitumab plus gemcitabine improves overall survival compared with placebo plus gemcitabine in the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Amgen is notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as in a separate ongoing phase II study in locally advanced pancreatic cancer.

Ganitumab is an investigational fully human monoclonal antibody that targets the type-1 insulin-like growth factor receptor (IGF1R).

For more information, visit the Amgen Web Site.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive